BACKGROUND AND OBJECTIVES: Recent reports suggest that CD4 (+)/CD56 (+)/lineage (-
) hematopoietic neoplasias are aggressive types of malignancies involving …

CD4+ CD56+ malignancies are rare hematologic neoplasms, which were recently shown to
correspond to the so-called type 2 dendritic cell (DC2) or plasmacytoid dendritic cells. This …

BACKGROUND AND OBJECTIVES: The CD4+ CD56+ lin-immunophenotype characterizes
rare malignancies, so far considered as arising from the transformation of NK progenitors …

We present a cohort of 22 patients with type 2 dendritic cell (DC2) acute leukemia (or blastic
plasmacytoid dendritic cell neoplasm-BPDCN, as it has been recently named), diagnosed in …

Objectives: Accumulating evidence suggests that non‐T, non‐B cell CD4+ CD56+
neoplasms with lymphoblastic morphology include clinically and immunophenotypically …

Dendritic cell neoplasms are rare tumors that are being recognized with increasing
frequency. They were previously classified as lymphomas, sarcomas, or histiocytic …

Abstract CD4+/CD56+ hematodermic neoplasm (“blastic natural killer [NK]-cell lymphoma”)
is a rare highly aggressive neoplasm associated with cutaneous manifestations followed by …

CD4+ CD56+ hematodermic neoplasms (HNs) with initial presentation in the skin are
characterized by highly aggressive behavior and poor prognosis. Recent studies indicate …

CD4+, CD56+ DC2 malignancies constitute a novel disease entity, which has recently been
shown to arise from a transformed lymphoid-related plasmacytoid dendritic cell (DC2) …

This work aims to demonstrate that CD4+ CD56+ malignancies arise from transformed cells
of the lymphoid-related plasmacytoid dendritic cell (pDC) subset. The analysis of malignant …